Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 256 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pioglitazone Hydrochloride Clear all
Recruiting Phase 2 Interventional

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

NCT05013255
View directory record Official record
Conditions
Breast Cancer, Muscle Fatigue
Interventions
Pioglitazone 15mg, Pioglitazone 30 mg
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 17, 2026, 4:35 PM EDT
Recruiting Phase 2 Interventional

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

NCT04501406
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Interventions
Pioglitazone, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 17, 2026, 4:35 PM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
View directory record Official record
Conditions
Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
781,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 17, 2026, 4:35 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)

NCT00787644
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Sep 17, 2026, 4:35 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

NCT06657209
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
Interventions
Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, Pioglitazone
Procedure · Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

NCT00402909
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Nateglinide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
28 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Results available

Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)

NCT00063622
View directory record Official record
Conditions
Liver Diseases
Interventions
Pioglitazone, Vitamin E, Matching placebo
Drug · Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 2 Interventional

GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes

NCT00280865
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tesaglitazar, Pioglitazone, Dietary and Lifestyle Modification Counseling
Drug · Behavioral
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 50 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
90
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2006 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Pioglitazone on Stress Reactivity and Alcohol Craving

NCT05107765
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 17, 2026, 4:35 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone

NCT01089790
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dutogliptin, Sitagliptin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 86 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
149
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 121 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

NCT00225264
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
45 Years to 85 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Albiglutide in Type 2 Diabetes

NCT00849056
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
310
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 250 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 4 Interventional

Pioglitazone Incretin Study

NCT00656864
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 1, 2011 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 4 Interventional Results available

Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss

NCT04370093
View directory record Official record
Conditions
Nephrolithiasis, Uric Acid
Interventions
Pioglitazone 45 mg, Weight Loss, Pioglitazone + Weight Loss
Drug · Behavioral · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 17, 2026, 4:35 PM EDT
Terminated Phase 3 Interventional Results available

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

NCT02284906
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
28
States / cities
Phoenix, Arizona • Sun City, Arizona • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 4 Interventional

Effect of Thiazolidinedione Treatment Vascular Risk Markers

NCT00571506
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Vascular Diseases
Interventions
Rosiglitazone, Pioglitazone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2009 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone in Thyroid Cancers

NCT01655719
View directory record Official record
Conditions
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
Interventions
Pioglitazone
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Aurora, Colorado • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Early Phase 1 Interventional

Mediators of Abnormal Reproductive Function in Obesity (MARO)

NCT01817400
View directory record Official record
Conditions
Infertility, Female, Obesity
Interventions
Microdialysis, Vascepa - Fish Oil, Aspirin, Pioglitazone
Other · Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 17, 2026, 4:35 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT01289639
View directory record Official record
Conditions
Fatty Liver
Interventions
fenofibrate, pioglitazone, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

NCT02222441
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib alone, Palbociclib plus Modafinil, Palbociclib plus pioglitazone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

NCT00212290
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes Mellitus
Interventions
pioglitazone, nateglinide, placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
55 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
2
States / cities
Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

NCT00665353
View directory record Official record
Conditions
HIV-1 and Hepatitis C Co-Infection
Interventions
pioglitazone, peginterferon, ribavirin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 17, 2026, 4:35 PM EDT
Completed Phase 3 Interventional Results available

PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

NCT00554853
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
pioglitazone, Sublingual nitroglycerine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 100 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 17, 2026, 4:35 PM EDT
Terminated Phase 4 Interventional Results available

Pioglitazone for the Treatment of Bipolar Depression

NCT01717040
View directory record Official record
Conditions
Bipolar Disorder, Insulin Resistance
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 17, 2026, 4:35 PM EDT